Frequent detection of high-risk HPV types other than HPV 16/18 in a cohort of French women who claimed to have been vaccinated
Archives of Virology · 2026
DOI: 10.1007/s00705-026-06722-1 ↗Kurz gefasst
Fachartikel in der Zeitschrift Archives of Virology, 2026. Verfasst von Sandy Gross und 6 weiteren Autor:innen. Beteiligte Einrichtung: Laboratoire de Virologie, CHU de Besançon, 3 Boulevard Fleming, Besançon, 25 030, France. Hauptthemen laut MEDLINE: Papillomavirus Infections, Papillomavirus Vaccines, Papillomaviridae. Die Arbeit nennt 18 Literaturangaben.
Abstract (Originalsprache)
This study aimed to estimate the prevalence and distribution of HPV in a cohort of vaccinated French women undergoing cervical cancer screening (CCS). Women vaccinated against HPV (either by the bivalent HPV16/18, the quadrivalent HPV6/11/16/18 or the nonavalent HPV6/11/16/18/31/33/45/52/58 vaccine) and for whom a cervical specimen had been collected were included. Detection and genotyping of 32 alpha-HPV genotypes (HPV6/11/16/18/26/31/33/35/39/40/42/43/44/45/51/52/53/54/56/58/59/61/62/66/67/68/70/73/81/82/83/89) was systematically performed (INNO-LIPA, Fujirebio). In a sub-study, high-risk HPV (hrHPV) was detected using two different HPV screening tests, according to the study period. 464 vaccinated women were included. Cytology was normal for 80.6% of them. The prevalence of alpha-HPV was 59.9% in vaccinated women and 25% of whom had multiple infections. The most prevalent hrHPV genotypes were HPV52 (8.2%), HPV51 (6.9%), and HPV56 (5.8%). HPV16 was detected in only 4.3% of women and was present in three of the four women with a high-grade lesion. In the sub-study, 238 women underwent hrHPV screening. The prevalence of hrHPV ranged from 27.9% to 57.1%, depending on the study period and CCS practices. Alpha-HPV, including high-risk HPV, are frequently detected in vaccinated French women. However, most of the genotypes that have been detected are not covered by the vaccines. The prevalence of HPV 16/18 is low, which confirms the efficacy of HPV vaccines. The implementation of the nonavalent vaccine may change the future epidemiology of hrHPV genotypes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratoire de Virologie, CHU de Besançon, 3 Boulevard Fleming, Besançon, 25 030, France.
- Laboratoire de Biologie Cellulaire, CHU Besançon, Besançon, France.
- Service de Gynécologie-Obstétrique, CHU Besançon, Besançon, France.
- Laboratoire d'Anatomie Pathologique, CHU Besançon, Besançon, France.
- Centre National de Référence Papillomavirus, CHU Besançon, Besançon, F-25000, France.
- Chrono-environnement (UMR 6249), Université Marie et Louis Pasteur, CNRS, Besançon, F-25000, France.
Zitieren
APA
Gross, S., Dalphin, L., Dor, F., Ramanah, R., Algros, M. P., Prétet, J. L., & Lepiller, Q. (2026). Frequent detection of high-risk HPV types other than HPV 16/18 in a cohort of French women who claimed to have been vaccinated. Archives of Virology. https://doi.org/10.1007/s00705-026-06722-1
Vancouver
Gross S, Dalphin L, Dor F, Ramanah R, Algros MP, Prétet JL, et al. Frequent detection of high-risk HPV types other than HPV 16/18 in a cohort of French women who claimed to have been vaccinated. Archives of Virology. 2026. doi:10.1007/s00705-026-06722-1
BibTeX
@article{Gross2026,
author = {Gross, Sandy and Dalphin, Louise and Dor, Fanny and Ramanah, Rajeev and Algros, Marie-Paule and Prétet, Jean-Luc and Lepiller, Quentin},
title = {Frequent detection of high-risk HPV types other than HPV 16/18 in a cohort of French women who claimed to have been vaccinated},
journal = {Archives of Virology},
year = {2026},
doi = {10.1007/s00705-026-06722-1}
}
EUVIMED